WCG
PFE icon

Weaver Consulting Group’s Pfizer PFE Stock Holding History

Weaver Consulting Group’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$288K Buy
11,973
+540
+5% +$14.1K 0.06% 235
2026
Q1 		$321K Buy
11,433
+244
+2% +$6.5K 0.08% 190
2025
Q4 		$279K Buy
11,189
+1,652
+17% +$41.7K 0.07% 213
2025
Q3 		$243K Sell
9,537
-620
-6% -$15.3K 0.06% 229
2025
Q2 		$246K Sell
10,157
-210
-2% -$4.9K 0.07% 207
2025
Q1 		$263K Sell
10,367
-308
-3% -$8.06K 0.08% 190
2024
Q4 		$283K Sell
10,675
-2,638
-20% -$71.6K 0.09% 167
2024
Q3 		$385K Buy
13,313
+65
+0.5% +$1.9K 0.12% 136
2024
Q2 		$371K Buy
13,248
+226
+2% +$6.22K 0.13% 131
2024
Q1 		$361K Buy
13,022
+2,980
+30% +$82.7K 0.13% 137
2023
Q4 		$289K Buy
+10,042
New +$304K 0.12% 149
2023
Q2 		– Sell
-5,179
Closed -$211K – 190
2023
Q1 		$211K Sell
5,179
-397
-7% -$17.1K 0.1% 168
2022
Q4 		$286K Buy
5,576
+18
+0.3% +$863 0.15% 134
2022
Q3 		$243K Sell
5,558
-80
-1% -$3.89K 0.14% 137
2022
Q2 		$296K Sell
5,638
-115
-2% -$5.86K 0.17% 124
2022
Q1 		$298K Sell
5,753
-396
-6% -$20.5K 0.14% 132
2021
Q4 		$363K Sell
6,149
-50
-0.8% -$2.48K 0.17% 110
2021
Q3 		$267K Buy
6,199
+56
+0.9% +$2.48K 0.15% 123
2021
Q2 		$241K Sell
6,143
-221
-3% -$8.59K 0.14% 126
2021
Q1 		$231K Buy
6,364
+573
+10% +$20.3K 0.14% 123
2020
Q4 		$213K Sell
5,791
-17
-0.3% -$624 0.13% 128
2020
Q3 		$202K Hold
5,808
– – 0.12% 120
2020
Q2 		$180K Buy
5,808
+318
+6% +$10.8K 0.1% 137
2020
Q1 		$170K Sell
5,490
-1,663
-23% -$56.7K 0.11% 118
2019
Q4 		$244K Buy
7,153
+2,338
+49% +$83.3K 0.13% 99
2019
Q3 		$177K Buy
4,815
+844
+21% +$30.7K 0.09% 115
2019
Q2 		$163K Hold
3,971
– – 0.09% 113
2019
Q1 		$162K Buy
+3,971
New +$159K 0.05% 243

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Weaver Consulting Group's PFE Position: Q2 2026 in Review

Weaver Consulting Group increased its Pfizer (PFE) stake by 4.7% in Q2 2026, buying an estimated $14.1K and bringing the position to 11,973 shares worth $288K. The position accounts for 0.06% of the portfolio, ranked #235.

Weaver Consulting Group first reported a position in PFE in Q1 2019 and has held it in 28 quarters since. The position peaked at $385K in Q3 2024. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Weaver Consulting Group held 11,973 shares of Pfizer worth $288K as of Q2 2026.
  • Weaver Consulting Group bought 540 Pfizer shares in Q2 2026, an estimated $14.1K.
  • Pfizer made up 0.06% of Weaver Consulting Group's portfolio in Q2 2026, its #235 holding.
  • Weaver Consulting Group first reported a position in Pfizer in Q1 2019 and has held it in 28 quarters since.
  • Weaver Consulting Group's Pfizer position peaked at $385K in Q3 2024.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Weaver Consulting Group's 13F filing for Q2 2026, filed 29 Jul 2026.